What Galderma Group Doubters Overlooked

Galderma Group spent this past year stacking concrete milestones, from Restylane Shaype’s EU approval for chin augmentation to Alastin’s rollout across Japan and Asia Pacific. Investors who held Galderma Group over the past year are up 32.1%, including dividends. If you had been weighing a position back on 5 November 2025, you would have needed to decide whether those kinds of product moves could justify that outcome before any of this news arrived.

If the move has made Galderma Group harder to judge, start where the gap is still open and scan 214 high quality undervalued stocks.

The Two Galderma Group Stories Investors Had To Weigh

The shares cost CHF146 at the start of the period, so any case for Galderma Group needed to start with whether that price matched the story you believed.

On the bullish side, the narrative pointed to a Fair Value of CHF164, a price implied by assumptions of 18.6% annual revenue growth and profit margins reaching 21.1% over three years. That view leaned on Nemluvio, premium aesthetics, and aging demographics supporting volume and pricing.

The more cautious view set Fair Value at CHF104 and treated margin pressure as central. Assumptions here included 14.1% yearly revenue growth, profit margins rising to 16.6%, and a future P/E of 29.6x in a world of tighter regulation and growing biosimilar competition.

What The Results Changed For The Galderma Group Argument

Net sales updates and H1 2026 results gave Galderma Group real numbers against both stories. Revenue reached US$3.148b in H1 2026 versus US$2.466b a year earlier, while net income rose from US$194m to US$444m. Net margin moved from 7.9% to 14.1%. The FDA delay for relabotulinumtoxinA in the US pulled the other way, so the evidence cut both ways.

The whole episode turned on what investors assumed about future profitability. For a different company, test that claim directly against reported net income, margin percentage, and any guidance changes rather than relying on product headlines alone.

What You Pay For Galderma Group After A 32% Run

With Galderma Group now at CHF195 after a 32.1% gain over the past year, the selected Narrative sees Fair Value below the current price. Its concern is less about demand and more about what it might cost to keep growth engines firing.

The Narrative leans on execution questions around Nemluvio, premium injectables and skincare acquisitions. A buyer today is effectively assuming these pillars scale smoothly worldwide, so the open question is how tariff pressure, integration spending and neuromodulator setbacks could affect that earnings path.

"Key Takeaways: Bearish analysts expect rising regulatory scrutiny, generic competition, and changing consumer preferences to keep forcing Galderma Group into expensive product and portfolio changes that weigh on profitability and market share. The main thing that has to go right is that Galderma Group turns Nemluvio, premium injectables, and high growth dermatological skincare into durable, globally scaled franchises that more than offset higher tariffs, acquisition integration costs, and any ongoing regulatory setbacks."

Not everyone reads the same price the same way. → See the lower figure this Narrative lands on, and how it gets there

Before The Next Story Makes Headlines

You may be late to this rally, but that does not have to mean arriving late to every opportunity. Start with companies whose prices leave room for a different view of their future. Here are three trading below our estimates.

• Company 1 - 17% below our estimate - focuses on antibiotic-loaded bone grafts that reduce systemic infection treatments and rehospitalisations.
• Company 2 - 33% below our estimate - uses its nutrition portfolio and dense retail network to steer shoppers toward higher-margin offerings.
• Company 3 - 43% below our estimate - targets faster subsea tiebacks by standardizing hardware and bundling engineering to streamline customer procurement.

That is three of the list. See the full list of 192 financially solid companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com